Takeshi Yoshimoto (Japan)

National Cerebral and Cardiovascular Center Department of Neurology
PERSONAL INFORMATION Date of Birth: 4 Jun 1982 Nationality: Japan Address: #201 5-39 Senrioka-shimmachi Settsu-shi Osaka 566-0002 Phone: +81-90-2297-6372 RESEARCH INTERESTS • Development of an algorithm for selection of clot removal devices in acute stroke by rapid identification of a genetic variation and serum biomarker • Association between juvenile stroke and the Moyamoya-related RNF213 p.R4810K polymorphism • Translational research in stroke EDUCATION M. D. Hiroshima University Faculty of Medicine March 2009 PROFESSIONAL EXPERIENCE July 2018 – Current Medical Doctor, Department of Neurology, National Cerebral and Cardiovascular Center (Dr. Ihara, Dr Toyoda) April 2018 – July 2017 Senior Resident, Department of Neurology, National Cerebral and Cardiovascular Center (Dr. Ihara) April 2015 – March 2018 Resident, Department of Neurology, National Cerebral and Cardiovascular Center (Dr. Ihara) April 2013 – March 2015 April 2012 – March 2013 Neurologist, Ota Memorial Hospital (Dr. Ota) Neurologist, Department of Clinical Neuroscience & Therapeutics, Hiroshima University Graduate School of Biomedical and Health Science (Dr. Matsumoto) April 2010 – March 2012 Intern, Fukushima Coop Hospital (Dr. Tashiro) HONORS & AWARDS Award for oral presentation at the 44th Annual Meeting of the Japan Stroke Society March 2019 Paul Dudley White International Scholar Award The American Heart Association March 2021

Author Of 1 Presentation

 Conference Calendar
Free Communication

LONG-TERM OUTCOME BETWEEN DIRECT ORAL ANTICOAGULANTS THERAPY AND ANTIPLATELET THERAPY AFTER PATENT FORAMEN OVALE-ASSOCIATED STROKE

Session Type
Free Communication
Session Name
190 - FREE COMMUNICATION: Stroke & Neurorehabilitation (ID 38)
Date
03.10.2021, Sunday
Session Time
11:30 - 12:38
Room
Free Communication A
Lecture Time
11:57 - 12:02
Presenter
  • Takeshi Yoshimoto (Japan)

Abstract

Background and Aims:

We aimed to clarify the long-term outcome of warfarin, direct oral anticoagulants (DOACs), or antiplatelet drugs for patent foramen ovale (PFO)-associated stroke.

Methods:

Consecutive PFO-associated stroke patients within six months were included from our single-center prospective database from November 2010 to April 2020. Patients with PFO closure were excluded. Subjects were divided into three subgroups by antithrombotic drugs (warfarin, DOAC, antiplatelet drug ). Each incidence rate for the composite event of recurrence ischemic stroke (IS) / cardiovascular death / major bleeding between groups using the Kaplan-Meier method. The hazard ratio (HR) adjusted for age and gender was analyzed from the Cox proportional hazard model.

Results:

The subjects were 231 patients (38% female, mean age ± standard deviation 74 ± 15 years), and the median observation period (IQR) was 2.3 (1.0–4.2) years. Annual incidence of complex events is warfarin 13 cases / 274 person-years (4.7%), DOAC 4 cases / 112 person-years (3.6%; adjusted hazard ratio [aHR] [95% confidence interval (CI)], 0.78 [0.28–2.33]), antiplatelet drugs 28 cases / 276 man-years (10.1%; aHR [95% CI], 2.11 [1.05–4.22]). In PFO-associated stroke high-risk cases (n=92), the annual incidence of compound events was warfarin 7 cases / 92 person-years (7.6%), DOAC 1 case / 42 person-years (2.4%; 0.34 [0.07–6.31]), 16 antiplatelet drugs / 86 man-years (18.6%; 2.11 [1.05–4.22]).

Conclusions:

The annual incidence of compound events in the patients with PFO-associated stroke and the high-risk PFO-associated stroke was significantly higher in antiplatelet drug cases than in warfarin cases.

Hide

Presenter of 1 Presentation

 Conference Calendar
Free Communication

LONG-TERM OUTCOME BETWEEN DIRECT ORAL ANTICOAGULANTS THERAPY AND ANTIPLATELET THERAPY AFTER PATENT FORAMEN OVALE-ASSOCIATED STROKE

Session Type
Free Communication
Session Name
190 - FREE COMMUNICATION: Stroke & Neurorehabilitation (ID 38)
Date
03.10.2021, Sunday
Session Time
11:30 - 12:38
Room
Free Communication A
Lecture Time
11:57 - 12:02
Presenter
  • Takeshi Yoshimoto (Japan)

Abstract

Background and Aims:

We aimed to clarify the long-term outcome of warfarin, direct oral anticoagulants (DOACs), or antiplatelet drugs for patent foramen ovale (PFO)-associated stroke.

Methods:

Consecutive PFO-associated stroke patients within six months were included from our single-center prospective database from November 2010 to April 2020. Patients with PFO closure were excluded. Subjects were divided into three subgroups by antithrombotic drugs (warfarin, DOAC, antiplatelet drug ). Each incidence rate for the composite event of recurrence ischemic stroke (IS) / cardiovascular death / major bleeding between groups using the Kaplan-Meier method. The hazard ratio (HR) adjusted for age and gender was analyzed from the Cox proportional hazard model.

Results:

The subjects were 231 patients (38% female, mean age ± standard deviation 74 ± 15 years), and the median observation period (IQR) was 2.3 (1.0–4.2) years. Annual incidence of complex events is warfarin 13 cases / 274 person-years (4.7%), DOAC 4 cases / 112 person-years (3.6%; adjusted hazard ratio [aHR] [95% confidence interval (CI)], 0.78 [0.28–2.33]), antiplatelet drugs 28 cases / 276 man-years (10.1%; aHR [95% CI], 2.11 [1.05–4.22]). In PFO-associated stroke high-risk cases (n=92), the annual incidence of compound events was warfarin 7 cases / 92 person-years (7.6%), DOAC 1 case / 42 person-years (2.4%; 0.34 [0.07–6.31]), 16 antiplatelet drugs / 86 man-years (18.6%; 2.11 [1.05–4.22]).

Conclusions:

The annual incidence of compound events in the patients with PFO-associated stroke and the high-risk PFO-associated stroke was significantly higher in antiplatelet drug cases than in warfarin cases.

Hide